Medicamen Biotech Share Price (MEDICAMEQ)
as on
| Source : NSE
Medicamen Biotech Stock Performance
as on August 21, 2025 at 4:01 PM IST
Day's Low
Day's High
₹355.55₹372.55
1.98%
Downside
2.70%
Upside
52 Week's Low
52 Week's High
₹342₹6305.72%
Downside
73.67%
Upside
| Market Stats | |
| Previous Close | ₹357.90 |
| Open | ₹361.50 |
| Volume | 18.71K |
| Upper Circuit | ₹429.45 |
| Lower Circuit | ₹286.35 |
| Day's Low | ₹355.55 |
| Day's High | ₹372.55 |
| 52 Week Low | ₹342 |
| 52 Week High | ₹630 |
| Returns % | |
| 1 Month Return | -8.96 % |
| 3 Month Return | -15.62 % |
| 1 Year Return | -13.2 % |
| 3 Year Return | -59.52 % |
| 5 Year Return | -34.28 % |
Medicamen Biotech Stock Fundamentals & Key Indicators
Check Medicamen Biotech market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹491.99 Cr
Return on Equity (ROE)
6.6
PE Ratio (TTM)
64.09
Return on capital employed (ROCE)
9.76
Industry PE ratio
43.37
Beta (LTM)
1.38
P/B Ratio
2.33
Dividend Yield
0.26
PEG Ratio
98.6
Quarterly Earnings Growth YOY
100
EPS (TTM)
7.47
Sector
Pharmaceuticals
Book Value
162.79
Technical Analysis
Bearish
View Technical Analysis
Medicamen Biotech Stock's Interest Amongst Investors
Medicamen Biotech Stock Valuation
Track how Medicamen Biotech P/E has moved over time to understand its valuation trends.
Medicamen Biotech in the last 5 years
Lowest (41.41x)
March 13, 2024
Industry (43.37x)
August 21, 2025
Today (64.09x)
August 21, 2025
Highest (132.87x)
December 6, 2024
Today’s Price to Earnings Ratio: 64.09x
Medicamen Biotech Ltd Financial Results
Get the annual and quarterly financial summary of Medicamen Biotech Ltd, including revenue, profit, loss and more.
Medicamen Biotech Earnings and Dividends
View detailed summary of the earnings and dividend history of Medicamen Biotech.
Medicamen Biotech Ltd Earnings Results
Medicamen Biotech Ltd’s net profit jumped 59.26% since last year same period to ₹2.15Cr in the Q1 2025-2026. On a quarterly growth basis, Medicamen Biotech Ltd has generated -10.42% fall in its net profits since last 3-months.
Read More about Earnings ResultsMedicamen Biotech Ltd Dividends May,2024
In the quarter ending March 2024, Medicamen Biotech Ltd has declared dividend of ₹1.00 per share on 29 May 2024 - translating a dividend yield of 0.84%.
Read More about Dividends
Medicamen Biotech Stock Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Medicamen Biotech.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 40.46% | 0.00 | |
| Foreign Institutions | 0% | ||
| Mutual Funds | 0% | 0.00 | |
| Retail Investors | 58.84% | 0.38 | |
| Others | 0.7% |
Medicamen Biotech Ltd vs Peers
Compare market cap, revenue, PE, and other key metrics of Medicamen Biotech with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| NA | 491.99 | -6.86% | 0.57 | 9 | 179 | |
| NA | 219.61 | 409.45% | 0.56 | -12 | 15 | |
| NA | 137.71 | -11.79% | 0.00 | 12 | 69 | |
| NA | 8.28 | 8.75% | 0.76 | NA | 27 | |
| NA | 264.04 | 0.76% | 0.00 | 9 | 162 |
Medicamen Biotech News & Key Events
Latest news and events in one place to help you make informed investing decisions in Medicamen Biotech.
Medicamen Biotech Secures USFDA Approval for Bortezomib - 03 Jun, 2025
Medicamen Biotech received its first ANDA approval from the USFDA for Bortezomib for Injection, enhancing its product portfolio and commitment to quality standards. Despite a decline in revenue, the approval signifies a strategic move into regulated markets.
Insights on Medicamen Biotech Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 2 quarters, 34.84 Cr → 43.52 Cr (in ₹), with an average increase of 19.9% per quarter
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 58.62% to 58.84% in Jun 2025 quarter
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 22.5% return, outperforming this stock by 36.2%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 40.46% of holdings in Jun 2025 quarter
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 140.0% return, outperforming this stock by 200.0%
NEGATIVE IMPACTPrice Dip
In the last 6 months, MEDICAMEQ stock has moved down by -35.2%
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 0.22% to 0.00% in Jun 2025 quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 3 quarters, 3.47 Cr → 2.15 Cr (in ₹), with an average decrease of 20.6% per quarter
About Medicamen Biotech Ltd
Revenue: ₹43.04Cr as on June 2025 (Q1 FY26)
Net Profit: ₹1.60Cr as on June 2025 (Q1 FY26)
Listing date: 27 Oct, 2021
Chairperson Name: Rahul Bishnoi
| Organisation | Medicamen Biotech Ltd |
| Industry | Pharmaceuticals |
| CEO | Rahul Bishnoi |
| E-voting on shares | Click here to vote |
FAQs
What is Medicamen Biotech share price today?
Medicamen Biotech share price today stands at ₹362.75, Open: ₹361.5, Previous Close: ₹357.9, High: ₹372.55, Low: ₹355.55, 52 Week High: ₹630, 52 Week Low: ₹342 as on .
How to buy Medicamen Biotech shares ?
To buy Medicamen Biotech shares, you need to follow these steps:
- Open a Demat account and Trading account on INDmoney
- Fund your Trading account
- Search for MEDICAMEQ or Medicamen Biotech Ltd on the INDmoney app to check live prices of the stock
- Click on Buy or SIP to place an order to invest in Medicamen Biotech shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
What is today's traded volume of Medicamen Biotech?
Today's traded volume of Medicamen Biotech is 18.71K. Which means that 18.71K shares of Medicamen Biotech were bought and sold on the stock market during today's trading session.
What is Medicamen Biotech's market cap today?
Today's market capitalisation of Medicamen Biotech is ₹491.99 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Medicamen Biotech?
Medicamen Biotech’s 52 week high is ₹630 and 52 week low is ₹342. The current share price of Medicamen Biotech is ₹362.75, which is -42.42% down from its 52 week high and 6.07% up from its 52 week low.